Biotech innovation in Spain: the European Investment Bank provides €20 million in financing to Sanifit to develop treatments for vascular calcification
- The EU bank will support Palma-based Sanifit in its work to develop cutting-edge solutions in biomedical research.
- The venture debt operation is supported by the Investment Plan for Europe.
Palma, Spain and San Diego, USA, 6 August 2020 – The European Investment Bank (EIB) is set to support the development of new treatments for progressive vascular calcification, an area of significant unmet medical need where there are currently no approved treatments. To this end, the EU bank will provide a €20 million loan to Spanish biopharmaceutical company Sanifit, which is developing novel treatments in two disease indications linked to calcification.
The EIB is advancing funds for this research, development and innovation (RDI) project by way of a venture debt operation with Investment Plan for Europe support, a financing instrument used by the EU bank to assist leading companies in innovative sectors. Since it was launched by the EIB under the Juncker Plan in 2016, this initiative has granted over €2 billion in financing for projects in areas such as robotics, artificial intelligence and biomedicine.
The EIB will provide Sanifit with long-term finance to drive the development of treatments for progressive vascular calcification disorders. The Company, founded out of the University of the Balearic Islands, has developed SNF472, a selective and potent inhibitor of hydroxyapatite (HAP) crystallisation, the final common pathway that leads to vascular calcification.
SNF472 is currently being investigated in a Phase 3 study for the treatment of calciphylaxis, a devastating rare disease where small blood vessels in skin and fat tissue are blocked due to severe calcification, leading to the death of approximately 55% of patients within the first year of diagnosis. A Phase 3 trial in a second indication, peripheral arterial disease, a major driver of morbidity and death in end-stage kidney disease patients, will launch in 2021.
EIB Vice-President Emma Navarro, responsible for the Bank’s operations in Spain, highlighted the “positive impact of this operation on strengthening the competitiveness of the European biomedical industry, a sector requiring large-scale investment and tailored financing solutions. We are delighted to help a leading Spanish company to develop new medical treatments for vascular calcification that will have clear benefits for human health and wellbeing. This agreement underscores the EIB’s commitment to supporting European innovation, which is now more vital than ever to promoting economic recovery and job creation.”
Dr Joan Perelló, Chief Executive Officer of Sanifit, commented: “The support of the EIB represents a significant endorsement of our technology and its potential to help patients suffering from debilitating conditions related to progressive vascular calcification. This is an extremely exciting time for Sanifit as we progress SNF472 through the clinic, and this further investment will be invaluable as we gather the late stage data required for approval, and to deliver treatment options to patients in need.”
The European Investment Bank (ElB) is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy objectives.
The Investment Plan for Europe was launched in November 2014 to reverse the downward trend in investment and foster economic recovery in Europe. Its innovative focus, whereby the EIB Group is provided with an EU budget guarantee, makes it possible to mobilise substantial public and private sector funding for investment in strategic sectors of the European economy.
The Investment Plan has to date leveraged €478.4 billion of investment and supported over 1.17 million emerging companies and SMEs throughout Europe. See the latest results of the Investment Plan for Europe by sector and country here, or go to Frequently Asked Questions.
More information on the results of the Investment Plan for Europe is available here.
For further enquiries:
Joan Perelló, CEO
Antonio Jiménez, VP Operations
For media enquiries:
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Sarah Wilson
Tel: +44 (0) 20 3709 5700
Tel: + 32 2 29 57361
Tel: +34 91 431 13 40
Follow us on Twitter @EU_Commission #investEU
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S.. The company’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study among hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and a Phase 3 trial in Peripheral Arterial Disease in End Stage Kidney Disease patients will launch in 2021. Sanifit has raised approximately $130M, including a 2019 Series D round of $61.8M (€55.2M) in mid-2019. For more information please visit www.sanifit.com.
SNF472 is an intravenous formulation of myo-inositol hexaphosphate with a novel mechanism of action for the treatment of cardiovascular diseases linked to calcification. SNF472 is in phase 3 development for calciphylaxis, a devastating rare disease which leads to the death of approximately 55% of patients within the first year of diagnosis. SNF472 has been granted orphan drug status for the treatment of calciphylaxis by both the EMA and FDA. Sanifit will also launch a phase 3 trial in Peripheral Arterial Disease in 2021 with SNF472, with additional indications related to progressive vascular calcification under consideration. SNF472 selectively blocks the progression of pathological cardiovascular calcification and poses an innovative solution for this unmet medical need.